Comparison
While PT-141 is FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women and is studied for sexual dysfunction in other populations, increasing sexual desire via CNS melanocortin pathways42101, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While PT-141 works as the synthetic melanocortin receptor agonist bremelanotide, an analog of α-MSH that activates central MC3R and MC4R to modulate neuronal circuits governing sexual desire and arousal3242101, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
PT-141 is 7 amino acids long, whereas Tirzepatide is longer as it has a length of 39 amino acids. PT-141 is made up of a sequence of sequence data not available in the current dataset. Tirzepatide is made up of a sequence of sequence data not available in the current dataset.
PT-141
POMC
Tirzepatide
Not assigned in the current dataset.